Hormonal
GLP-1-based therapies (GLP-1 receptor agonists and DPP-4 inhibitors) are associated with a class-wide risk of acute pancreatitis, driven by a mechanism of supraphysiological GLP-1 receptor activation causing exocrine pancreatic duct proliferation and potential occlusion.
If you are taking a GLP-1 drug (like Ozempic, Trulicity, or Victoza) or a DPP-4 inhibitor (like Januvia), be aware of the potential risk of pancreatitis. If you experience severe, persistent abdominal pain, stop the medication and seek medical attention immediately. The paper suggests this risk is real and mechanistically plausible, not just a rare side effect.
We conclude that the balance of evidence does suggest an association between widely used GLP-1–based therapies and acute pancreatitis, suggesting a class effect, and that this is underpinned by a plausible mechanism.
Why this rating
The paper relies on FDA adverse event reporting (signal detection), animal models, and observational studies, but acknowledges conflicting epidemiological data and lack of definitive human histological proof of causality.
Source
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Peter C. Butler et al. · Diabetes Care · 2013
DOI 10.2337/dc12-2713
More from this paper
- GLP-1-based therapies may accelerate the progression of premalignant pancreatic lesions (PanINs) to pancreatic cancer in individuals with pre-existing dysplasia, acting as a growth factor rather than an initiator.Moderate
- GLP-1-based therapies are associated with an increased risk of thyroid cancer, specifically medullary thyroid cancer and papillary thyroid cancer, due to GLP-1 receptor expression in thyroid C-cells and papillary cancer cells.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →